Stock listing

NASDAQ:IRON Disc Medicine, Inc. Stock

Home listing (NASDAQ) of Disc Medicine, Inc.

Follow Disc Medicine, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:IRON

$75.14 USD -2.84 (-3.6%)

Close on Nov 20, 2026

Past year -16.8% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$74.54 – $77.01 USDNov 20, 2026
Volume
561,636 sharesNov 20, 2026
Market cap
$3.42B USDAt the close on Nov 20, 2026 · price × 45.54M shares outstanding
52-week range
$40.00 – $99.50 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$70.28M USDMedian day 669,013 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Disc Medicine, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:IRON · Home$75.14 USD-2.84 (-3.6%)561,636$75.20$77.01$74.54$77.98Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:IRON · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$75.14-2.84-3.6%$75.20$77.01$74.54561,636
$77.98+1.41+1.8%$76.52$79.71$75.25947,865
$76.57-0.020.0%$76.69$77.90$75.34520,620
$76.59-3.41-4.3%$80.12$80.37$76.40816,009
$80.00-3.23-3.9%$83.00$83.00$79.73778,194
$83.23-3.85-4.4%$86.16$87.14$82.66761,213
$87.08+2.44+2.9%$85.24$87.51$83.50669,013
$84.64+3.38+4.2%$80.58$86.26$80.531,925,406
$81.26+2.35+3.0%$80.83$81.54$76.86912,029
$78.91+0.44+0.6%$78.65$79.52$77.67717,525
$78.47-4.81-5.8%$83.00$85.00$78.31930,368
$83.28+2.12+2.6%$81.50$83.57$80.781,428,044
$81.16+2.54+3.2%$79.41$81.72$79.081,543,632
$78.62-2.22-2.7%$80.99$81.39$78.04525,360
$80.84-2.00-2.4%$82.79$83.03$78.61684,972
$82.84-0.36-0.4%$83.51$85.00$82.22686,454
$83.20+3.30+4.1%$78.88$83.64$78.881,071,161
$79.90+2.24+2.9%$77.23$80.50$76.501,469,720
$77.66+3.15+4.2%$74.80$78.03$74.801,203,251
$74.51-0.52-0.7%$74.29$75.56$74.011,963,099
$75.03-0.97-1.3%$75.25$78.00$74.771,588,205
$76.00-3.48-4.4%$77.80$81.50$75.894,639,550
$79.48+0.55+0.7%$79.21$80.00$74.522,206,622
$78.93+22.09+38.9%$72.70$80.22$69.988,493,179
$56.84+0.19+0.3%$56.56$57.24$55.00569,100
$56.65+0.91+1.6%$56.66$58.09$55.95699,800
$55.74-0.86-1.5%$56.21$58.84$55.48430,700
$56.60-3.88-6.4%$60.16$60.48$56.47599,000
$60.48-1.58-2.5%$62.20$62.76$60.36657,200
$62.06+1.29+2.1%$60.67$63.50$60.03691,100
$60.77-0.41-0.7%$60.71$61.58$58.22846,800
$61.18-0.47-0.8%$61.20$62.97$60.02562,800
$61.65-1.68-2.7%$63.70$64.66$61.311,422,400
$63.33-1.18-1.8%$65.13$65.57$63.01456,300
$64.51+0.90+1.4%$64.56$66.55$63.81684,700
$63.61-1.85-2.8%$65.27$65.94$63.50771,800
$65.46-0.41-0.6%$66.08$66.08$64.24671,500
$65.87+0.95+1.5%$64.93$66.29$64.05784,100
$64.92-0.32-0.5%$64.83$66.26$63.96480,500
$65.24-1.20-1.8%$66.89$66.89$64.59427,200
$66.44+0.35+0.5%$66.09$66.58$64.31455,600
$66.09-2.39-3.5%$68.54$68.95$65.31541,800
$68.48-0.010.0%$69.65$69.79$67.68450,800
$68.49-1.04-1.5%$69.84$69.84$67.16406,500
$69.53+0.35+0.5%$69.13$69.60$67.711,077,100
$69.18+0.61+0.9%$69.84$72.07$68.47621,200
$68.57+1.27+1.9%$67.88$70.00$67.49433,800
$67.30-1.62-2.4%$68.86$69.45$66.72603,900
$68.92-1.14-1.6%$70.06$70.83$67.52695,000
$70.06-4.08-5.5%$74.66$75.00$69.28621,000
$74.14-2.37-3.1%$75.89$76.59$73.16480,900
$76.51-0.33-0.4%$76.55$77.27$75.24719,500
$76.84-2.39-3.0%$76.71$79.13$74.50463,300
$79.23-0.14-0.2%$78.14$80.01$78.14204,800
$79.37-0.68-0.8%$80.34$80.89$78.28501,000
$80.05+1.38+1.8%$79.44$81.01$77.68522,500
$78.67+0.020.0%$78.56$79.95$75.88549,400
$78.65-1.38-1.7%$79.19$80.53$77.50882,000
$80.03-2.52-3.1%$81.79$82.70$79.77665,600
$82.55-0.12-0.1%$82.25$83.20$81.10324,100
$82.67+0.26+0.3%$82.28$83.63$81.54586,900
$82.41+1.47+1.8%$81.99$83.59$81.77320,944
$80.94+1.13+1.4%$79.88$82.74$79.33277,237
$79.81+0.97+1.2%$79.50$80.00$77.99370,400
$78.84-1.48-1.8%$79.45$80.15$78.49333,600

Splits

1 split · NASDAQ:IRON · every price before a split is adjusted for it

DayRatioWhat
1-for-30Consolidation
Ticker
NASDAQ:IRON
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Disc Medicine, Inc. news

Disc Medicine, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
27 in the last 12 months · 132 in all · newest Nov 5, 2026 · oldest 2021
Decks
17 decks · latest Oct 19, 2026

Where Disc Medicine, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:IRON · Home listing · This pageNASDAQUnited StatesUSD
BOATS:IRONBOATSUnited StatesUSD

Valuation

Price/book 5.7× against a median of 3.9×: 9th lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$2.80B USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
5.7×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.1×
Beta vs S&P 500
0.94

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Disc Medicine, Inc. · NASDAQ:IRONUS$3.42BUS$2.80Bn/an/an/a5.7×n/a0.1×0.94
Tango Therapeutics, Inc. · NASDAQ:TNGXUS$3.68BUS$2.74Bn/an/an/a3.8×n/a0.0×1.41
Xenon Pharmaceuticals Inc. · NASDAQ:XENEUS$3.64BUS$2.70Bn/an/an/a3.2×n/a0.0×0.80
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Class A · SSE:688336US$3.57BUS$3.43B7.6×5.1×n/a2.7×69.9%0.0×n/a
Relay Therapeutics, Inc. · NASDAQ:RLAYUS$3.56BUS$2.74Bn/a265×n/a4.3×n/a0.0×1.48
Enliven Therapeutics, Inc. · NASDAQ:ELVNUS$3.42BUS$2.54Bn/an/an/a3.9×n/a0.0×0.89
Viridian Therapeutics, Inc. · NASDAQ:VRDNUS$3.40BUS$2.69Bn/a102×n/a5.9×n/a0.4×1.00
Parabilis Medicines, Inc. · NASDAQ:PBLSUS$3.39BUS$2.53Bn/an/an/a3.4×n/a0.0×n/a
Caliway Biopharmaceuticals Co Ltd · TWSE:6919US$3.38BUS$3.27Bn/an/an/a12.7×n/a0.0×n/a
Amylyx Pharmaceuticals, Inc. · NASDAQ:AMLXUS$3.35BUS$2.58Bn/an/an/a4.4×n/a0.0×1.21
Iovance Biotherapeutics, Inc. · NASDAQ:IOVAUS$3.19BUS$2.86Bn/a7.5×n/a3.9×−58.2%0.1×1.62
Median of the othersUS$3.41BUS$2.72B7.6×54.9×3.9×5.8%0.0×1.21

Forecasts

12 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.

Price target
127.69 USD · Analysts' mean
EPS, year to Dec 2026
-6.11 · 9 analysts

Team and board

Officers

OfficerRole
John QuiselChief Executive Officer
Jean FranchiChief Financial Officer
Jonathan YuChief Operating Officer
Rahul KharaChief Legal Officer
Joseph BeaulieuSVP, Finance
Melanie ChinSVP, Clinical Development and Head of Medical Affairs
Sonia RazzettiSVP, Quality
Srikanth VenkatramanSVP, Head of Chemistry
Hua YangChief Early Development Officer
Lisa Amaya PriceChief Human Resources Officer
Pamela StephensonChief Commercial Officer
Rahul Rajan KaushikChief Technical Officer
Steve CafféChief Regulatory Officer
Will SavageChief Medical Officer

Board

DirectorRole
Hua YangChief Early Development Officer
Jean FranchiChief Financial Officer
John QuiselChief Executive Officer
Jonathan YuChief Operating Officer
Joseph BeaulieuSVP, Finance
Lisa Amaya PriceChief Human Resources Officer
Melanie ChinSVP, Clinical Development and Head of Medical Affairs
Pamela StephensonChief Commercial Officer
Rahul KharaChief Legal Officer
Rahul Rajan KaushikChief Technical Officer
Sonia RazzettiSVP, Quality
Srikanth VenkatramanSVP, Head of Chemistry

Events

QuarterResultsShare move
Q3 2026Nov 5, 2026 · Before open−5.8%
Q2 2026Jul 30, 2026 · Before open+7.5%
Q1 2026May 5, 2026 · Before open−0.1%
Q4 2025Feb 26, 2026−0.4%
Q3 2025Nov 6, 2025 · Before open−1.5%
Q2 2025Aug 7, 2025 · Before open−3.3%
Q1 2025May 7, 2025 · Before open+2.3%
Q4 2024Mar 19, 2025 · Before open+1.7%
Q3 2024Nov 12, 2024 · Before open−5.0%
Q2 2024Aug 8, 2024 · Before open+3.8%
All 20 quarters
QuarterResultsShare move
Q1 2024May 9, 2024 · Before open+4.9%
Q4 2023Mar 21, 2024 · Before open−7.5%
Q3 2023Nov 9, 2023 · Before open+1.4%
Q2 2023Aug 11, 2023 · Before open+1.7%
Q1 2023May 15, 2023 · Before open−3.6%
Q4 2022Mar 31, 2023 · Before open−3.9%
Q3 2022Nov 10, 2022 · Before open+0.6%
Q2 2022Aug 11, 2022 · Before open−4.0%
Q1 2022May 6, 2022 · Before open−1.3%
Q4 2021Mar 10, 2022 · Before open−3.9%

Open Events

Decks

DeckKindSlidesDate
Corporate Update (October 2026)Corporate update22 slidesOct 19, 2026
Investor Presentation (September 2026)Investor deck63 slidesSeptember 2026
Investor Presentation (June 2026)Investor deck41 slidesJun 15, 2026
Corporate Update (February 2026)Corporate update11 slidesFeb 17, 2026
J.P. Morgan 44th Annual Healthcare Conference 2026Conference31 slidesJan 12, 2026
2025 ASH Management CallConference31 slidesDec 8, 2025
Investor Presentation (October 2025)Investor deck61 slidesOct 20, 2025
2024 ASH Management CallConference45 slidesDec 9, 2024
Corporate Update (November 2024)Corporate update16 slidesNov 4, 2024
2024 EHA Management CallConference56 slidesJun 14, 2024
All 17 decks
DeckKindSlidesDate
Technical Presentation (December 2023)Technical49 slidesDec 12, 2023
ASH 2023Conference15 slidesDecember 2023
Investor Presentation (June 2023)Investor deck54 slidesJun 9, 2023
Merger or Acquisition (January 2023)Merger or acquisition13 slidesJan 23, 2023
Merger or Acquisition (August 2022)Merger or acquisition52 slidesAug 10, 2022
ASH 2021 (American Society of Hematology Annual Meeting)Conference13 slidesNov 8, 2021
Technical PresentationTechnical19 slides

Open Decks

Financings

RaiseDate
Public offering of common stock
Made bigger: US$450M · US$75 a share · Jefferies +6
Dealers: Jefferies (co-lead), Leerink Partners (co-lead), Morgan Stanley (co-lead), Cantor (co-lead), LifeSci Capital, BMO Capital Markets, H.C. Wainwright & Co.
Use of proceeds: Fund research and clinical development, support potential commercialization of bitopertin for EPP and XLP, pre-commercialization activities, working capital
Oct 21, 2026
Public offering of common stock and pre-funded warrants
Made bigger: about US$225M · US$84 a share · Jefferies +5
Dealers: Jefferies (co-lead), Leerink Partners (co-lead), Morgan Stanley (co-lead), Cantor (co-lead), Wedbush PacGrow, H.C. Wainwright & Co.
Use of proceeds: Support potential commercialization of bitopertin for EPP and XLP, fund research and clinical development, working capital and general corporate purposes
Oct 21, 2025
Public offering of common stock and pre-funded warrants
Made bigger: about US$225.5M · US$55 a share · Jefferies +7
Dealers: Jefferies (co-lead), Leerink Partners (co-lead), Stifel (co-lead), Cantor (co-lead), BMO Capital Markets, LifeSci Capital, Wedbush PacGrow, H.C. Wainwright & Co.
Use of proceeds: Research and clinical development of product candidates, potential commercialization of bitopertin for EPP and XLP, working capital and general corporate purposes
Jan 22, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as FS Development Corp., a blank check company (SPAC). Priced at US$10.00 a share on Aug 11, 2020.

Price
US$10.00 a share
Shares offered
10,500,000 shares of Class A common stock
Offering size
US$105 million
Underwriters' option
Up to 1,575,000 more shares
Listing
FSDC on the Nasdaq Capital Market
Underwriter
Jefferies
Shares delivered
On or about Aug 14, 2020

Steps

StepWhen
Draft sent to the SEC in confidenceJul 2, 2020
Filed publiclyJul 24, 2020
Amended onceAug 7, 2020
Shares registered with an exchangeAug 10, 2020
Declared effective by the SECAug 11, 2020
Final prospectus, with the priceAug 13, 2020

Open IPO · From the cover of the final prospectus (424B4) filed Aug 13, 2020

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020
Revenue000000
Cost of revenue281.0K156.0K100.0K300.0K192.0K322.0K
Gross profit-281.0K-156.0K-100.0K-300.0K-192.0K-322.0K
Research and development170.6M96.7M69.3M33.4M25.2M28.2M
Selling, general and administrative65.4M33.0M21.9M14.0M5.76M5.87M
Operating income-236.0M-129.7M-91.1M-47.5M-30.9M-34.0M
Depreciation and amortization281.0K156.0K100.0K89.0K32.0K322.0K
EBITDA-235.7M-129.6M-91.0M-47.4M-30.9M-33.7M
Interest expense3.61M572.0K0737.0K2.16M6.83M
Income before tax-211.8M-109.0M-76.3M-46.8M-36.0M-40.8M
Income tax361.0K355.0K99.0K05.04M6.83M
Net income-212.2M-109.4M-76.4M-46.8M-36.0M-40.8M
Earnings per share, basic-6.01-3.96-3.42-45.05-40.95-2.70
Earnings per share, diluted-6.01-3.96-3.42-45.05-40.95-2.70

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash and equivalents91.1M192.4M360.4M194.6M88.0M4.50M
Short-term investments700.0M297.4M0
Current assets803.9M493.6M365.7M198.5M90.5M5.07M
Property, plant and equipment1.16M751.0K170.0K168.0K106.0K294.0K
Total assets806.9M496.8M368.0M200.2M92.4M8.32M
Accounts payable9.02M7.95M12.6M16.2M2.56M2.38M
Current liabilities36.6M23.3M21.4M22.6M13.4M24.9M
Long-term debt29.2M28.3M404.0K4.95M
Total debt29.2M28.3M01.33M7.06M14.0M
Total liabilities67.1M53.2M22.9M23.6M14.8M30.2M
Shareholders' equity739.8M443.6M345.1M176.6M-64.2M-28.8M
Shares outstanding37.9M29.9M24.4M17.4M909.4K15.6M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash from operations-180.4M-93.9M-73.5M-42.3M-27.5M-32.7M
Capital spending-933.0K-505.0K-89.0K-151.0K-68.0K-22.0K
Free cash flow-181.3M-94.4M-73.6M-42.4M-27.6M-32.7M
Cash from investing-394.3M-292.3M-89.0K-151.0K-68.0K-22.0K
Cash from financing473.4M218.3M239.4M149.0M89.9M34.2M
Change in cash-101.3M-167.9M165.8M106.6M62.3M1.52M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 12, 2026Insider tradeSEC
144 · Notice of proposed saleNov 10, 2026Other filingsSEC
424B5 · ProspectusNov 5, 2026Offer documentSEC
10-Q · Quarterly reportNov 5, 2026Quarterly reportSEC
8-K · Current reportNov 5, 2026ResultsSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 26, 2026Big-stake noticeSEC
8-K · Current reportOct 22, 2026ResultsSEC
4 · Change in ownershipOct 21, 2026Insider tradeSEC
424B5 · ProspectusOct 21, 2026Offer documentSEC
144 · Notice of proposed saleOct 21, 2026Other filingsSEC
Show 200 filings
FilingDateTypeFiled with
144 · Notice of proposed saleOct 21, 2026Other filingsSEC
144 · Notice of proposed saleOct 21, 2026Other filingsSEC
144 · Notice of proposed saleOct 21, 2026Other filingsSEC
144 · Notice of proposed saleOct 20, 2026Other filingsSEC
144 · Notice of proposed saleOct 20, 2026Other filingsSEC
144 · Notice of proposed saleOct 20, 2026Other filingsSEC
144 · Notice of proposed saleOct 20, 2026Other filingsSEC
424B5 · ProspectusOct 19, 2026Offer documentSEC
144 · Notice of proposed saleOct 19, 2026Other filingsSEC
144 · Notice of proposed saleOct 19, 2026Other filingsSEC
144 · Notice of proposed saleOct 19, 2026Other filingsSEC
144 · Notice of proposed saleOct 19, 2026Other filingsSEC
8-K · Current reportOct 19, 2026Current reportSEC
4 · Change in ownershipSep 16, 2026Insider tradeSEC
4 · Change in ownershipSep 15, 2026Insider tradeSEC
144 · Notice of proposed saleSep 11, 2026Other filingsSEC
8-K · Current reportSep 10, 2026Current reportSEC
4 · Change in ownershipSep 9, 2026Insider tradeSEC
144 · Notice of proposed saleSep 4, 2026Other filingsSEC
144 · Notice of proposed saleSep 4, 2026Other filingsSEC
144 · Notice of proposed saleSep 4, 2026Other filingsSEC
144 · Notice of proposed saleSep 4, 2026Other filingsSEC
4 · Change in ownershipSep 3, 2026Insider tradeSEC
144 · Notice of proposed saleSep 3, 2026Other filingsSEC
144 · Notice of proposed saleSep 3, 2026Other filingsSEC
144 · Notice of proposed saleSep 3, 2026Other filingsSEC
144 · Notice of proposed saleSep 3, 2026Other filingsSEC
144 · Notice of proposed saleSep 2, 2026Other filingsSEC
144 · Notice of proposed saleSep 2, 2026Other filingsSEC
144 · Notice of proposed saleSep 2, 2026Other filingsSEC
144 · Notice of proposed saleSep 2, 2026Other filingsSEC
4 · Change in ownershipAug 26, 2026Insider tradeSEC
4 · Change in ownershipAug 18, 2026Insider tradeSEC
144 · Notice of proposed saleAug 17, 2026Other filingsSEC
4 · Change in ownershipAug 14, 2026Insider tradeSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
144 · Notice of proposed saleAug 6, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 6, 2026Big-stake noticeSEC
10-Q · Quarterly reportJul 30, 2026Quarterly reportSEC
8-K · Current reportJul 30, 2026ResultsSEC
4 · Change in ownershipJul 14, 2026Insider tradeSEC
144 · Notice of proposed saleJul 13, 2026Other filingsSEC
4 · Change in ownershipJul 9, 2026Insider tradeSEC
144 · Notice of proposed saleJul 7, 2026Other filingsSEC
4 · Change in ownershipJun 30, 2026Insider tradeSEC
4 · Change in ownershipJun 30, 2026Insider tradeSEC
8-K · Current reportJun 30, 2026Material contractSEC
144 · Notice of proposed saleJun 26, 2026Other filingsSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
8-K · Current reportJun 24, 2026Meeting outcomeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
144 · Notice of proposed saleJun 22, 2026Other filingsSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
144 · Notice of proposed saleJun 18, 2026Other filingsSEC
144 · Notice of proposed saleJun 18, 2026Other filingsSEC
144 · Notice of proposed saleJun 16, 2026Other filingsSEC
10-Q · Quarterly reportMay 5, 2026Quarterly reportSEC
8-K · Current reportMay 5, 2026ResultsSEC
ARS · Annual report to shareholdersApr 28, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 28, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 28, 2026Meeting noticeSEC
4 · Change in ownershipApr 15, 2026Insider tradeSEC
4 · Change in ownershipApr 15, 2026Insider tradeSEC
144 · Notice of proposed saleApr 13, 2026Other filingsSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
144 · Notice of proposed saleMar 2, 2026Other filingsSEC
4 · Change in ownershipFeb 27, 2026Insider tradeSEC
8-K · Current reportFeb 27, 2026Current reportSEC
S-8 · Registration statement for employee plansFeb 26, 2026Offer documentSEC
10-K · Annual reportFeb 26, 2026Annual reportSEC
8-K · Current reportFeb 26, 2026ResultsSEC
144 · Notice of proposed saleFeb 25, 2026Other filingsSEC
4 · Change in ownershipFeb 19, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 18, 2026Other filingsSEC
4 · Change in ownershipFeb 17, 2026Insider tradeSEC
4 · Change in ownershipFeb 17, 2026Insider tradeSEC
4 · Change in ownershipFeb 17, 2026Insider tradeSEC
4 · Change in ownershipFeb 17, 2026Insider tradeSEC
4 · Change in ownershipFeb 17, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 17, 2026Other filingsSEC
144 · Notice of proposed saleFeb 17, 2026Other filingsSEC
144 · Notice of proposed saleFeb 17, 2026Other filingsSEC
144 · Notice of proposed saleFeb 17, 2026Other filingsSEC
144 · Notice of proposed saleFeb 17, 2026Other filingsSEC
144 · Notice of proposed saleFeb 17, 2026Other filingsSEC
8-K · Current reportFeb 17, 2026Current reportSEC
8-K · Current reportFeb 13, 2026Current reportSEC
4 · Change in ownershipFeb 11, 2026Insider tradeSEC
4 · Change in ownershipFeb 11, 2026Insider tradeSEC
4 · Change in ownershipFeb 11, 2026Insider tradeSEC
4 · Change in ownershipFeb 11, 2026Insider tradeSEC
4 · Change in ownershipFeb 11, 2026Insider tradeSEC
4 · Change in ownershipFeb 11, 2026Insider tradeSEC
4 · Change in ownershipJan 21, 2026Insider tradeSEC
8-K · Current reportJan 12, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeJan 7, 2026Big-stake noticeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
144 · Notice of proposed saleJan 2, 2026Other filingsSEC
4 · Change in ownershipDec 29, 2025Insider tradeSEC
4 · Change in ownershipDec 19, 2025Insider tradeSEC
4 · Change in ownershipDec 18, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedDec 17, 2025Big-stake noticeSEC
144 · Notice of proposed saleDec 17, 2025Other filingsSEC
144 · Notice of proposed saleDec 17, 2025Other filingsSEC
144 · Notice of proposed saleDec 17, 2025Other filingsSEC
144 · Notice of proposed saleDec 17, 2025Other filingsSEC
144 · Notice of proposed saleDec 17, 2025Other filingsSEC
4 · Change in ownershipDec 16, 2025Insider tradeSEC
4 · Change in ownershipDec 16, 2025Insider tradeSEC
144 · Notice of proposed saleDec 16, 2025Other filingsSEC
144 · Notice of proposed saleDec 16, 2025Other filingsSEC
144 · Notice of proposed saleDec 16, 2025Other filingsSEC
144 · Notice of proposed saleDec 16, 2025Other filingsSEC
144 · Notice of proposed saleDec 16, 2025Other filingsSEC
144 · Notice of proposed saleDec 16, 2025Other filingsSEC
144 · Notice of proposed saleDec 16, 2025Other filingsSEC
144 · Notice of proposed saleDec 16, 2025Other filingsSEC
144 · Notice of proposed saleDec 16, 2025Other filingsSEC
144 · Notice of proposed saleDec 15, 2025Other filingsSEC
144 · Notice of proposed saleDec 15, 2025Other filingsSEC
144 · Notice of proposed saleDec 15, 2025Other filingsSEC
144 · Notice of proposed saleDec 15, 2025Other filingsSEC
144 · Notice of proposed saleDec 15, 2025Other filingsSEC
4 · Change in ownershipDec 15, 2025Insider tradeSEC
144 · Notice of proposed saleDec 15, 2025Other filingsSEC
144 · Notice of proposed saleDec 15, 2025Other filingsSEC
144 · Notice of proposed saleDec 15, 2025Other filingsSEC
144 · Notice of proposed saleDec 15, 2025Other filingsSEC
144 · Notice of proposed saleDec 15, 2025Other filingsSEC
144 · Notice of proposed saleDec 15, 2025Other filingsSEC
144 · Notice of proposed saleDec 12, 2025Other filingsSEC
144 · Notice of proposed saleDec 12, 2025Other filingsSEC
144 · Notice of proposed saleDec 12, 2025Other filingsSEC
144 · Notice of proposed saleDec 12, 2025Other filingsSEC
144 · Notice of proposed saleDec 12, 2025Other filingsSEC
144 · Notice of proposed saleDec 11, 2025Other filingsSEC
8-K · Current reportDec 8, 2025Current reportSEC
4 · Change in ownershipNov 13, 2025Insider tradeSEC
144 · Notice of proposed saleNov 12, 2025Other filingsSEC
10-Q · Quarterly reportNov 6, 2025Quarterly reportSEC
8-K · Current reportNov 6, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 5, 2025Big-stake noticeSEC
4 · Change in ownershipOct 24, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 22, 2025Big-stake noticeSEC
8-K · Current reportOct 22, 2025Material contractSEC
424B5 · ProspectusOct 21, 2025Offer documentSEC
144 · Notice of proposed saleOct 20, 2025Other filingsSEC
144 · Notice of proposed saleOct 20, 2025Other filingsSEC
144 · Notice of proposed saleOct 20, 2025Other filingsSEC
424B5 · ProspectusOct 20, 2025Offer documentSEC
8-K · Current reportOct 20, 2025ResultsSEC
144 · Notice of proposed saleOct 17, 2025Other filingsSEC
144 · Notice of proposed saleOct 17, 2025Other filingsSEC
144 · Notice of proposed saleOct 17, 2025Other filingsSEC
4 · Change in ownershipOct 17, 2025Insider tradeSEC
8-K · Current reportOct 17, 2025Current reportSEC
144 · Notice of proposed saleOct 16, 2025Other filingsSEC
144 · Notice of proposed saleOct 16, 2025Other filingsSEC
144 · Notice of proposed saleOct 15, 2025Other filingsSEC
144 · Notice of proposed saleOct 15, 2025Other filingsSEC
4 · Change in ownershipOct 9, 2025Insider tradeSEC
144 · Notice of proposed saleOct 8, 2025Other filingsSEC
144 · Notice of proposed saleOct 7, 2025Other filingsSEC
8-K · Current reportOct 6, 2025Management or board changeSEC
4 · Change in ownershipSep 18, 2025Insider tradeSEC
4 · Change in ownershipSep 11, 2025Insider tradeSEC
4 · Change in ownershipAug 26, 2025Insider tradeSEC
144 · Notice of proposed saleAug 22, 2025Other filingsSEC
144 · Notice of proposed saleAug 22, 2025Other filingsSEC
4 · Change in ownershipAug 15, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 15, 2025Big-stake noticeSEC
144 · Notice of proposed saleAug 14, 2025Other filingsSEC
144 · Notice of proposed saleAug 14, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
144 · Notice of proposed saleAug 13, 2025Other filingsSEC
144 · Notice of proposed saleAug 13, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 12, 2025Big-stake noticeSEC
4 · Change in ownershipAug 7, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 7, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 7, 2025Quarterly reportSEC
8-K · Current reportAug 7, 2025ResultsSEC
144 · Notice of proposed saleAug 5, 2025Other filingsSEC

This page holds 200 of 780 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Disc Medicine, Inc.’s releases · as of Oct 29, 2026

Common shares
45,540,842
Fully diluted
45,540,842

Fully diluted

LineSharesAs of
Common shares45,540,842Oct 29, 2026

Share count over time

CountShares
Oct 29, 202645,540,842

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueChange vs Jun 30Filed
Fidelity4.8M10.5%US$314M−91,328Nov 10, 2026
BlackRock2.53M5.6%US$166M+64,964Nov 13, 2026
Ra Capital Management, L.P.2.45M5.4%US$160MNo changeNov 16, 2026
Vanguard1.91M4.2%US$125M+3,567Nov 13, 2026
JPMorgan1.81M4.0%US$119M−63,625Nov 12, 2026
Wellington1.76M3.9%US$115M+15,139Nov 16, 2026
T. Rowe Price1.66M3.6%US$108M−220KNov 16, 2026
Vestal Point Capital, LP1.64M3.6%US$107M+85,000Nov 16, 2026
State Street1.41M3.1%US$92M−243KNov 12, 2026
Atlas Venture Life Science Advisors, LLC1.38M3.0%US$90.6M−130KNov 10, 2026
Show 50 holders
HolderSharesOf the companyValueChange vs Jun 30Filed
TCG Crossover Management, LLC1.34M2.9%US$87.8MNo changeNov 16, 2026
Assenagon Asset Management S.A.1.12M2.5%US$73.3M+351KOct 15, 2026
Opaleye Management Inc.1.09M2.4%US$71.7M+240KNov 16, 2026
Logos Global Management LP1.01M2.2%US$66.4M+140KNov 19, 2026
Woodline Partners LP958K2.1%US$62.7MNo changeNov 16, 2026
Frazier Life Sciences Management, L.P.935K2.1%US$61.2M−420KNov 16, 2026
Siren, L.L.C.888K2.0%US$58.2MNo changeNov 12, 2026
Geode Capital798K1.8%US$52.2M+8,003Nov 6, 2026
Deerfield Management Company, L.P.657K1.4%US$43MNo changeNov 16, 2026
Saturn V Capital Management LP613K1.3%US$40.1M+87,931Nov 16, 2026
abrdn598K1.3%US$39.1M+160KNov 10, 2026
Dimensional590K1.3%US$38.7M+21,459Nov 4, 2026
Two Sigma571K1.3%US$37.4M+434KNov 16, 2026
Bellevue Group AG560K1.2%US$36.7MNo changeNov 16, 2026
Armistice Capital, LLC500K1.1%US$32.7M+40,000Nov 16, 2026
Loomis Sayles & Co L P440K0.97%US$28.8M+58,164Nov 12, 2026
Checkpoint Capital L.P.400K0.88%US$26.2M+160KNov 13, 2026
Palo Alto Investors LP397K0.87%US$26M−20,117Nov 16, 2026
Eventide Asset Management, LLC396K0.87%US$25.9M+156Nov 13, 2026
Foresite Capital Management V, LLC374K0.82%US$24.5MNo changeNov 16, 2026
Baker Bros. Advisors LP350K0.77%US$22.9MNo changeNov 16, 2026
BNP Paribas311K0.68%US$20.3M+87,657Nov 12, 2026
Schwab283K0.62%US$18.5M+25,980Nov 16, 2026
Goldman Sachs278K0.61%US$18.2M+181KNov 16, 2026
Octagon Capital Advisors LP270K0.59%US$17.7MNo changeNov 16, 2026
Northern Trust266K0.59%US$17.4M+1,494Nov 16, 2026
Algert Global LLC252K0.55%US$16.5M+200KNov 17, 2026
Jane Street245K0.54%US$16.1M+229KNov 12, 2026
Bank of America236K0.52%US$15.5M+101KNov 16, 2026
Bvf Inc233K0.51%US$15.3M−920KNov 16, 2026
Sofinnova Investments, Inc.232K0.51%US$15.2M+85,389Nov 16, 2026
First Turn Management, LLC221K0.48%US$14.4MNewNov 16, 2026
BNY202K0.44%US$13.2M−3,048Nov 5, 2026
UBS195K0.43%US$12.8M−29,945Nov 16, 2026
Catalio Capital Management, LP173K0.38%US$11.3M+13,325Nov 16, 2026
Jennison Associates LLC156K0.34%US$10.2M−284KNov 13, 2026
Trexquant Investment LP143K0.31%US$9.33M+34,805Nov 16, 2026
Bain Capital Life Sciences Investors, LLC141K0.31%US$9.25MNo changeNov 16, 2026
Qube Research & Technologies Ltd137K0.30%US$8.95M+124KNov 13, 2026
Nuveen132K0.29%US$8.65M+71,826Nov 10, 2026

This page holds 50 of 229 holders. Open Shareholders

Funds

HolderSharesOf the companyValueChangeAs of
Strategic Advisers Fidelity U.S. Total Stock Fund1.89M4.1%US$131M+233KMay 31, 2026
Vanguard Total Stock Market Index Fund971K2.1%US$71M−18,308Jun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF959K2.1%US$70.1M−53,447Jun 30, 2026
iShares Russell 2000 ETF740K1.6%US$54.1M+70,252Jun 30, 2026
JPMorgan Mid Cap Growth Fund648K1.4%US$47.4M+262KJun 30, 2026
T. Rowe Price New Horizons Fund, Inc.567K1.2%US$41.5M+61,774Jun 30, 2026
Select Biotechnology Portfolio455K1.00%US$31.6M−77,400May 31, 2026
Select Health Care Portfolio450K0.99%US$31.3M−200KMay 31, 2026
Eventide Healthcare & Life Sciences Fund395K0.87%US$28.9MNo changeJun 30, 2026
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund376K0.82%US$27.5M+58,100Jun 30, 2026
Show 50 holders
HolderSharesOf the companyValueChangeAs of
Vanguard Extended Market Index Fund367K0.81%US$26.8M+12,583Jun 30, 2026
Fidelity Small Cap Index Fund309K0.68%US$23.8M+37,627Jul 31, 2026
Fidelity Small Cap Growth Fund278K0.61%US$21.4M−120KJul 31, 2026
JPMorgan Small Cap Growth Fund274K0.60%US$20.1M−14,411Jun 30, 2026
iShares Russell 2000 Growth ETF261K0.57%US$19.1M+36,715Jun 30, 2026
Fidelity Stock Selector Small Cap Fund222K0.49%US$17.1M+34,500Jul 31, 2026
VIP Mid Cap Portfolio209K0.46%US$15.3MNo changeJun 30, 2026
Loomis Sayles Small Cap Growth Fund207K0.45%US$15.1M+29,159Jun 30, 2026
Fidelity Advisor Health Care Fund200K0.44%US$15.4M−145KJul 31, 2026
PGIM Jennison Health Sciences Fund198K0.43%US$13.8MNo changeMay 29, 2026
iShares Biotechnology ETF196K0.43%US$14.4M−18,678Jun 30, 2026
JNL/JPMorgan MidCap Growth Fund175K0.39%US$12.8M+69,378Jun 30, 2026
Fidelity Extended Market Index Fund164K0.36%US$11.4M−2,277May 31, 2026
Schwab U.S. Small-Cap ETF152K0.33%US$10.6M−2,651May 31, 2026
Fidelity U.S. Equity Central Fund145K0.32%US$10.6M−45,000Jun 30, 2026
Fidelity Small Cap Growth K6 Fund144K0.32%US$11.1M−54,440Jul 31, 2026
Vanguard Russell 2000 Index Fund141K0.31%US$9.82M+17,561May 31, 2026
Vanguard Explorer Fund133K0.29%US$10.3MNewJul 31, 2026
T. Rowe Price Health Sciences Fund, Inc.132K0.29%US$9.68M−54,246Jun 30, 2026
Fidelity Series Small Cap Opportunities Fund127K0.28%US$9.8M−4,100Jul 31, 2026
U.S. Small Cap Portfolio122K0.27%US$9.37M+51,923Jul 31, 2026
Dimensional U.S. Small Cap ETF120K0.26%US$9.23M+7,628Jul 31, 2026
U.S. Micro Cap Portfolio96,9640.21%US$7.47M+18,734Jul 31, 2026
JPMorgan Mid Cap Equity Fund91,7940.20%US$6.71M+38,315Jun 30, 2026
JPMorgan Small Cap Blend Fund87,1660.19%US$6.38M−6,019Jun 30, 2026
Dimensional U.S. Core Equity 2 ETF83,2950.18%US$6.41M+23,051Jul 31, 2026
Fidelity Advisor Biotechnology Fund80,9220.18%US$6.23M−61,400Jul 31, 2026
VIP Health Care Portfolio80,0000.18%US$5.85M−34,000Jun 30, 2026
Fidelity Advisor Small Cap Fund77,0000.17%US$5.36MNo changeMay 31, 2026
Vanguard Health Care Index Fund72,9900.16%US$5.08M−247May 31, 2026
Schwab Small-Cap Index Fund68,5840.15%US$5.28M+8,230Jul 31, 2026
Victory Science & Technology Fund64,6340.14%US$4.98MNo changeJul 31, 2026
T. Rowe Price Small-Mid Cap ETF63,7850.14%US$4.67M+26,609Jun 30, 2026
Fidelity Total Market Index Fund59,6780.13%US$4.15MNo changeMay 31, 2026
BNY Mellon Small/Mid Cap Growth Fund57,8730.13%US$4.23M−7,457Jun 30, 2026
Small Cap Growth Stock Portfolio56,2270.12%US$4.11MNo changeJun 30, 2026
The Hartford Healthcare Fund55,9070.12%US$4.3MNo changeJul 31, 2026
Fidelity Growth Company Fund54,6920.12%US$3.8MNo changeMay 31, 2026
Mid Cap Growth Stock Portfolio54,4290.12%US$3.98M+21,662Jun 30, 2026
Select Pharmaceuticals Portfolio53,8000.12%US$3.74MNo changeMay 31, 2026

This page holds 50 of 220 holders. Open Shareholders

Insider trades

InsiderTradeSharesPriceValueDate
Savage William Jacob
Officer: Chief Medical Officer
Sale16,035USD 85.09US$1.36MNov 10, 2026
Bitterman Kevin
Director
Sale13,783USD 80.23US$1.11MOct 21, 2026
Bitterman Kevin
Director
Sale11,470USD 80.23US$920KOct 21, 2026
Bitterman Kevin
Director
Sale266USD 80.23US$21,341Oct 21, 2026
Bitterman Kevin
Director
Sale2,869USD 79.95US$229KOct 20, 2026
Bitterman Kevin
Director
Sale2,388USD 79.95US$191KOct 20, 2026
Bitterman Kevin
Director
Sale55USD 79.95US$4,397Oct 20, 2026
Bitterman Kevin
Director
Sale5,937USD 79.97US$475KOct 19, 2026
Bitterman Kevin
Director
Sale4,942USD 79.97US$395KOct 19, 2026
Bitterman Kevin
Director
Sale115USD 79.97US$9,197Oct 19, 2026
Show 50 trades
InsiderTradeSharesPriceValueDate
Bitterman Kevin
Director
Sale27,136USD 70.11US$1.9MSep 11, 2026
Bitterman Kevin
Director
Sale912USD 79.96US$72,924Sep 4, 2026
Bitterman Kevin
Director
Sale759USD 79.96US$60,690Sep 4, 2026
Bitterman Kevin
Director
Sale18USD 79.96US$1,439Sep 4, 2026
Bitterman Kevin
Director
Sale2,810USD 79.98US$225KSep 3, 2026
Bitterman Kevin
Director
Sale2,339USD 79.98US$187KSep 3, 2026
Bitterman Kevin
Director
Sale54USD 79.98US$4,319Sep 3, 2026
Bitterman Kevin
Director
Sale26,542USD 80.17US$2.13MSep 2, 2026
Bitterman Kevin
Director
Sale22,090USD 80.17US$1.77MSep 2, 2026
Bitterman Kevin
Director
Sale511USD 80.17US$40,967Sep 2, 2026
Bitterman Kevin
Director
Sale10USD 80.98US$810Sep 2, 2026
Bitterman Kevin
Director
Sale9USD 80.98US$729Sep 2, 2026
Bitterman Kevin
Director
Sale2USD 80.98US$162Sep 2, 2026
Bitterman Kevin
Director
Sale70USD 79.95US$5,597Sep 1, 2026
Bitterman Kevin
Director
Sale58USD 79.95US$4,637Sep 1, 2026
Bitterman Kevin
Director
Sale1USD 79.95US$80Sep 1, 2026
Yu Jonathan Yen-Wen
Officer: Chief Operating Officer
Sale8,796USD 83.12US$731KAug 25, 2026
Yu Jonathan Yen-Wen
Officer: Chief Operating Officer
Sale300USD 82.53US$24,759Aug 24, 2026
Quisel John D
Director, Officer: Chief Executive Officer
Sale8,400USD 78.11US$656KAug 17, 2026
Quisel John D
Director, Officer: Chief Executive Officer
Sale12,712USD 79.20US$1.01MAug 17, 2026
Quisel John D
Director, Officer: Chief Executive Officer
Sale11,888USD 79.84US$949KAug 17, 2026
Yu Jonathan Yen-Wen
Officer: Chief Operating Officer
Sale804USD 82.64US$66,443Aug 12, 2026
Khara Rahul
Officer: Chief Legal Officer
Sale5,000USD 80.00US$400KAug 6, 2026
Quisel John D
Director, Officer: Chief Executive Officer
Sale9,704USD 74.27US$721KJul 13, 2026
Quisel John D
Director, Officer: Chief Executive Officer
Sale16,896USD 74.95US$1.27MJul 13, 2026
Quisel John D
Director, Officer: Chief Executive Officer
Sale6,400USD 76.05US$487KJul 13, 2026
Yu Jonathan Yen-Wen
Officer: Chief Operating Officer
Sale100USD 82.50US$8,250Jul 7, 2026
Khara Rahul
Officer: Chief Legal Officer
Sale1,649USD 75.00US$124KJun 29, 2026
Yu Jonathan Yen-Wen
Officer: Chief Operating Officer
Sale300USD 72.50US$21,750Jun 26, 2026
Khara Rahul
Officer: Chief Legal Officer
Sale851USD 75.00US$63,825Jun 26, 2026
Yu Jonathan Yen-Wen
Officer: Chief Operating Officer
Sale9,700USD 72.66US$705KJun 22, 2026
Quisel John D
Director, Officer: Chief Executive Officer
Sale22,927USD 69.92US$1.6MJun 18, 2026
Quisel John D
Director, Officer: Chief Executive Officer
Sale9,522USD 70.70US$673KJun 18, 2026
Quisel John D
Director, Officer: Chief Executive Officer
Sale1,551USD 71.61US$111KJun 18, 2026
Khara Rahul
Officer: Chief Legal Officer
Sale5,400USD 69.94US$378KJun 18, 2026
Khara Rahul
Officer: Chief Legal Officer
Sale1,600USD 70.73US$113KJun 18, 2026
Khara Rahul
Officer: Chief Legal Officer
Sale500USD 71.62US$35,810Jun 18, 2026
Yu Jonathan Yen-Wen
Officer: Chief Operating Officer
Sale11,651USD 68.76US$801KJun 16, 2026
Yu Jonathan Yen-Wen
Officer: Chief Operating Officer
Sale6,961USD 69.92US$487KJun 16, 2026
Franchi Jean M.
Officer: Chief Financial Officer
Sale6,257USD 69.24US$433KApr 14, 2026

This page holds 50 of 53 trades. Open Shareholders

Big stakes

HolderStakeSharesDate
FMR LLC12.80%4.88MJun 30, 2026
AI DMI LLC6.60%2.94MOct 22, 2026
Ra Capital Management, L.P.5.90%2.23MDec 30, 2025
Orbimed Advisors LLC4.50%1.56MMar 10, 2025
Atlas Venture Fund X, L.P.2.20%813KDec 12, 2025

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Carl Gordon
Other companies: ADARx Pharmaceuticals, Inc. (Co-head Global Private Equity at OrbiMed Advisors · Since at least Sep 24, 2026); Electra Therapeutics, Inc. (Director · Since at least Sep 18, 2026); BlossomHill Therapeutics, Inc. (Board Member · Since at least Aug 6, 2026); Scribe Therapeutics Inc. (Director · Since at least Jul 23, 2026); Compass Therapeutics, Inc. (Founding Member, Managing Partner, and Co-Head of Global Private Equity, OrbiMed Advisors LLC · Since at least Jun 17, 2020); Keros Therapeutics, Inc. (Director · Since at least Apr 7, 2020); MBX Biosciences, Inc. (Director · Sep 12, 2024 – Feb 14, 2025 · Past); ArriVent BioPharma, Inc. (Director · Jan 25, 2024 – Jan 30, 2024 · Past); Theseus Pharmaceuticals Inc (Director · Oct 6, 2021 – Feb 14, 2024 · Past); Terns Pharmaceuticals, Inc. (Director · Feb 4, 2021 – Jul 15, 2024 · Past); Kinnate Biopharma Inc (Director · Dec 2, 2020 – Apr 3, 2024 · Past); Adicet Bio, Inc. (Director · Sep 15, 2020 – Aug 21, 2024 · Past); ORIC Pharmaceuticals, Inc. (Director · Apr 23, 2020 – Jun 16, 2021 · Past); SpringWorks Therapeutics Inc (Director · Sep 12, 2019 – Sep 12, 2019 · Past); Prevail Therapeutics Inc (Director · Jun 19, 2019 – Jan 22, 2021 · Past); Turning Point Therapeutics Inc (Director · Apr 16, 2019 – Jun 15, 2020 · Past); Alector, Inc. (Director · Feb 6, 2019 – May 10, 2019 · Past); Armo Biosciences Inc. (Director · Jan 25, 2018 – Jun 22, 2018 · Past); X4 Pharmaceuticals, Inc. (Director · Nov 15, 2017 – Jun 5, 2018 · Past); Cartesian Therapeutics, Inc. (Director · Jun 21, 2016 – Jun 27, 2016 · Past); Intellia Therapeutics, Inc. (Director · May 5, 2016 – May 18, 2017 · Past); Acceleron Pharma Inc (Director · Sep 18, 2013 – Sep 18, 2013 · Past); Pacira BioSciences, Inc. (Director · Feb 2, 2011 – Feb 8, 2011 · Past); Amarin Corporation plc (Director · Dec 30, 2010 – Sep 4, 2012 · Past); BioCryst Pharmaceuticals, Inc. (Director · May 17, 2006 – May 17, 2006 · Past)
Director · Feb 5, 2021 – Oct 4, 2021 · Past
David Lubner
Other companies: Braveheart Bio, Inc. (Director · Since at least Aug 5, 2026); Crescent Biopharma, Inc. (Director · Since at least Jun 13, 2025); CARGO Therapeutics, Inc. (Director · Since at least Nov 9, 2023); Arcellx Inc (Director · Since at least Feb 3, 2022); Dyne Therapeutics, Inc. (Board Member · Since at least Jul 31, 2020); Vor Biopharma Inc. (Director · Feb 4, 2021 – May 22, 2025 · Past); POINT Biopharma Global Inc (Director · Jul 7, 2020 – Dec 26, 2023 · Past); Nightstar Therapeutics PLC (Director · Jan 1, 2019 – Jun 7, 2019 · Past); Ra Pharmaceuticals Inc (Executive VP and CFO · Oct 25, 2016 – Apr 2, 2020 · Past); Tetraphase Pharmaceuticals Inc (SVP and CFO · Mar 19, 2013 – Aug 14, 2015 · Past)
Director · Feb 5, 2021 – Oct 4, 2021 · Past
Deepika Pakianathan
Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Mereo BioPharma Group plc (Director · Since at least Jan 1, 2024); Theravance Biopharma, Inc. (Director · Since at least Jul 1, 2020); Karyopharm Therapeutics Inc. (Director · Since at least Nov 5, 2013); Pardes Biosciences Inc (Director · Feb 16, 2021 – Dec 23, 2021 · Past); Calithera Biosciences, Inc. (Director · Oct 1, 2014 – Jan 27, 2023 · Past); Alder BioPharmaceuticals Inc (Director · May 7, 2014 – May 23, 2018 · Past); OncoMed Pharmaceuticals Inc (Director · Jul 17, 2013 – Apr 23, 2019 · Past); Alexza Pharmaceuticals Inc (Director · Mar 8, 2006 – Jun 21, 2016 · Past)
Director · Aug 11, 2020 – Aug 11, 2020 · Past
Liam Ratcliffe
Other companies: OnKure Therapeutics, Inc. (Director · Since at least Mar 27, 2026); Upstream Bio, Inc. (Director · Since at least Oct 10, 2024); Climb Bio, Inc. (Director · Aug 9, 2021 – Jun 26, 2024 · Past); Passage Bio, Inc. (Director · Feb 27, 2020 – May 27, 2021 · Past); Arvinas, Inc. (Director · Sep 26, 2018 – Jun 16, 2022 · Past); Aptinyx Inc (Director · Jun 20, 2018 – Mar 29, 2019 · Past); Cogent Biosciences, Inc. (Director · Mar 28, 2018 – Jun 14, 2019 · Past); Deciphera Pharmaceuticals LLC (Director · Sep 27, 2017 – May 17, 2018 · Past); PDS Biotechnology Corporation (Director · Jun 21, 2016 – Mar 15, 2019 · Past)
Director · Since at least Dec 29, 2022
Jean George
Other companies: Cyteir Therapeutics Inc (Director · Jun 17, 2021 – Feb 14, 2024 · Past); Astria Therapeutics Inc (Director · Jun 24, 2015 – Jun 7, 2018 · Past); Calithera Biosciences, Inc. (Director · Oct 1, 2014 – Jun 11, 2021 · Past); Acceleron Pharma Inc (Director · Sep 18, 2013 – Jan 22, 2020 · Past); Portola Pharmaceuticals Inc (Director · May 21, 2013 – May 28, 2013 · Past); Zeltiq Aesthetics Inc (Director · Oct 18, 2011 – Jul 22, 2015 · Past)
Director · Feb 5, 2021 – Feb 5, 2021 · Past
Jim Tananbaum
Other companies: Latigo Biotherapeutics, Inc. (Director · Since at least Aug 6, 2026); Alumis Inc. (Director · Since at least Jun 27, 2024); Quantum-Si Incorporated (Director · Jun 10, 2021 – Jun 10, 2021 · Past); Pardes Biosciences Inc (President and CEO, Director · Feb 16, 2021 – Aug 31, 2023 · Past); Kinnate Biopharma Inc (Director · Dec 2, 2020 – Apr 3, 2024 · Past)
Director · Aug 11, 2020 – Oct 4, 2021 · Past
Jason Rhodes
Other companies: Dyne Therapeutics, Inc. (Chairman · Since at least Sep 16, 2020); Generation Bio Co (Director · Since at least Jun 11, 2020); Replimune Group, Inc. (Director · Jul 19, 2018 – Apr 1, 2022 · Past); Epizyme Inc (President, CFO and Treasurer · May 30, 2013 – Sep 22, 2014 · Past)
Director · Feb 5, 2021 – Oct 4, 2021 · Past
Jay Backstrom
Other companies: Agios Pharmaceuticals, Inc. (Independent Director · Since at least Jul 8, 2025); LAVA Therapeutics NV (Director · Since at least Jan 1, 2025); Scholar Rock Holding Corporation (CHIEF EXECUTIVE OFFICER, Director · Sep 20, 2022 – Mar 10, 2025 · Past); Acceleron Pharma Inc (EVP, Research and Development · Dec 10, 2019 – Nov 19, 2021 · Past)
Director · Dec 29, 2022 – Dec 29, 2022 · Past
Robert F. Carey
Other companies: Beyond Air, Inc. (Chairman of the Board · Since at least Feb 11, 2019); Sangamo Therapeutics, Inc. (Director · Since at least Jun 14, 2016); Argos Therapeutics Inc (Director · Sep 18, 2015 – Jan 19, 2017 · Past); Horizon Pharma PLC (EVP, Chief Business Officer · Mar 5, 2014 – Mar 23, 2019 · Past)
Director · Aug 11, 2020 – Aug 11, 2020 · Past
Brian Piekos
Other companies: KalVista Pharmaceuticals, Inc. (Chief Financial Officer · Since at least Sep 9, 2024); Elicio Therapeutics, Inc. (Chief Financial Officer · Jun 1, 2023 – Feb 1, 2024 · Past); AMAG Pharmaceuticals Inc (Chief Financial Officer · Jun 9, 2020 – Nov 16, 2020 · Past)
CFO · Feb 12, 2021 – May 31, 2022 · Past
All 46 people
PersonSeat
Gregg Beloff
Other companies: Pandion Therapeutics Inc (See Remarks · Jul 16, 2020 – Apr 1, 2021 · Past); Synlogic Inc (See Remarks · Oct 21, 2019 – Dec 6, 2021 · Past); Dare Bioscience, Inc. (CFO · May 27, 2015 – Jan 5, 2017 · Past)
Chief Financial Officer · Feb 5, 2021 – Feb 5, 2021 · Past
Jean Franchi
Other companies: Biodesix, Inc. (Director · Since at least Oct 27, 2020); Replimune Group, Inc. (Chief Financial Officer · Dec 9, 2019 – May 16, 2023 · Past); Merrimack Pharmaceuticals Inc (Chief Financial Officer · Feb 15, 2018 – Dec 11, 2018 · Past)
Chief Financial Officer · Since at least Feb 7, 2024
Mark Chin
Other companies: Pyxis Oncology, Inc. (Director · Oct 7, 2021 – Mar 31, 2022 · Past); Enliven Therapeutics, Inc. (Director · Mar 11, 2020 – Jun 2, 2022 · Past); Harpoon Therapeutics Inc (Director · Nov 9, 2018 – Mar 8, 2024 · Past)
Director · Since at least Dec 29, 2022
Michael E Rome
Other companies: Theseus Pharmaceuticals Inc (Director · Oct 6, 2021 – Oct 6, 2021 · Past); Pardes Biosciences Inc (Vice President, Director · Feb 16, 2021 – Feb 16, 2021 · Past); Kinnate Biopharma Inc (Director · Dec 2, 2020 – Apr 3, 2024 · Past)
Vice President, Director · Aug 11, 2020 – Aug 11, 2020 · Past
Nadim Ahmed
Other companies: Cullinan Therapeutics, Inc. (President and Chief Executive Officer · Since at least Oct 18, 2021); Bristol-Myers Squibb Company (EVP and President, Hematology · Nov 20, 2019 – Dec 31, 2020 · Past); Celgene Corporation (PRES., GLOBAL HEM. AND ONC. · Jun 13, 2018 – Nov 20, 2019 · Past)
Director · Since at least Jul 14, 2025
Donald William Nicholson
Other companies: Generation Bio Co (Director · Since at least Jun 11, 2020); Kymera Therapeutics, Inc. (Director · Aug 20, 2020 – Jun 15, 2022 · Past)
Director · Since at least Dec 29, 2022
Georges Gemayel
Other companies: Supernus Pharmaceuticals, Inc. (INDEPENDENT NON-EXECUTIVE DIRECTOR · Since at least Feb 21, 2020); Momenta Pharmaceuticals Inc (Director · Jun 19, 2019 – Oct 1, 2020 · Past)
Director · Since at least Apr 29, 2021
John Quisel
Other companies: Gossamer Bio, Inc. (Director · Since at least Nov 28, 2023); Acceleron Pharma Inc (EVP, Chief Business Officer · Sep 18, 2013 – Jan 2, 2020 · Past)
Chief Executive Officer · Since at least Dec 29, 2022
Kevin Bitterman
Other companies: Akero Therapeutics Inc (Director · Jun 19, 2019 – Jun 1, 2021 · Past); Editas Medicine, Inc. (Director · Feb 2, 2016 – Jun 15, 2017 · Past)
Director · Since at least Dec 29, 2022
Mona Ashiya
Other companies: Shattuck Labs, Inc. (Director · Since at least Aug 25, 2025); Sierra Oncology Inc (Director · Nov 22, 2019 – Jul 1, 2022 · Past)
Director · Since at least Dec 29, 2022
Pamela Stephenson
Other companies: Albireo Pharma Inc (Chief Commercial Officer · Mar 25, 2019 – Mar 2, 2023 · Past); Zynerba Pharmaceuticals Inc (Director · Feb 19, 2019 – Oct 10, 2023 · Past)
Chief Commercial Officer · Since at least Feb 26, 2024
Tuyen Ong
Other companies: Nightstar Therapeutics PLC (Chief Development Officer · Jan 1, 2019 – Jun 7, 2019 · Past); PTC Therapeutics, Inc. (Chief Medical Officer · Apr 22, 2016 – Jan 3, 2017 · Past)
Director · Feb 5, 2021 – Oct 4, 2021 · Past
William Richard White
Other companies: Ventyx Biosciences Inc (Director · Since at least Oct 20, 2021); Akero Therapeutics Inc (Chief Financial Officer · Since at least Jun 19, 2019)
Director · Since at least Dec 29, 2022
Daniel Dubin
Other companies: Pardes Biosciences Inc (Director · Feb 16, 2021 – Dec 23, 2021 · Past)
Director · Aug 11, 2020 – Aug 11, 2020 · Past
Dennis D Ryan
Other companies: Pardes Biosciences Inc (Chief Financial Officer · Feb 16, 2021 – Feb 16, 2021 · Past)
Chief Financial Officer · Aug 11, 2020 – Aug 11, 2020 · Past
Jason Patrick Meyenburg
Other companies: Sucampo Pharmaceuticals Inc (Chief Commercial Officer · Jun 1, 2017 – Feb 13, 2018 · Past)
Chief Executive Officer, Director · Feb 5, 2021 – Jan 3, 2022 · Past
Joseph Beaulieu
Other companies: Epizyme Inc (See Remarks · Aug 9, 2022 – Aug 12, 2022 · Past)
SVP, Finance · Since at least Nov 5, 2026
Samuel B Barone
Other companies: Adverum Biotechnologies Inc (SVP, Clinical Development · Jul 30, 2014 – Feb 9, 2017 · Past)
Chief Medical Officer · Apr 12, 2021 – Apr 12, 2021 · Past
Vikram Bajaj
Other companies: Quantum-Si Incorporated (Director · Jun 15, 2022 – Jun 16, 2022 · Past)
Director · Aug 11, 2020 – Aug 11, 2020 · Past
Brian Richard MacDonaldChief Innovation Officer · Dec 29, 2022 – Jun 28, 2023 · Past
Hua YangChief Early Development Officer · Since at least Nov 5, 2026
Joanne BryceChief Financial Officer · Dec 29, 2022 – Jan 10, 2024 · Past
Jonathan YuChief Operating Officer · Since at least Dec 29, 2022
Lisa Amaya PriceChief Human Resources Officer · Since at least Jan 12, 2026
Marc UknisChief Medical Officer · Feb 5, 2021 – Feb 5, 2021 · Past
Melanie ChinSVP, Clinical Development and Head of Medical Affairs · Since at least May 14, 2025
Precillia RedmondChief People Officer · Feb 5, 2021 – Feb 23, 2021 · Past
Rahul KharaChief Legal Officer · Since at least Dec 29, 2022
Rahul Rajan KaushikChief Technical Officer · Since at least Nov 12, 2024
Scott LauderChief Technology Officer · Feb 5, 2021 – Feb 23, 2021 · Past
Sonia RazzettiSVP, Quality · Since at least Nov 5, 2026
Srikanth VenkatramanSVP, Head of Chemistry · Since at least Nov 5, 2026
Steve CafféChief Regulatory Officer · Since at least Nov 12, 2024
Walter StrappsChief Scientific Officer · Feb 5, 2021 – Apr 28, 2021 · Past
William Jacob SavageChief Medical Officer · Since at least Dec 29, 2022
Will SavageChief Medical Officer · Since at least Apr 15, 2026

Open People

Log in to ask 6ix AI your own questions about Disc Medicine, Inc.